Lipids & metabolic liver disease
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Study context
- Population
- Participants of a 48-week phase 2 obesity study with MASLD and ≥10% liver fat
- Participants
- 98 participants
- Comparison
- Once-weekly subcutaneous retatrutide vs placebo
- Primary endpoint
- Mean relative change from baseline in liver fat
- Follow-up
- 24 weeks
Methodological detailsdouble-blind, placebo-controlled, phase 2a, substudy
- Double-blind
- Placebo-controlled
- Phase 2a
- Substudy
Primary result
As reported in the abstract
1 mg
−42.9%
mean
4 mg
−57.0%
mean
8 mg
−81.4%
mean
12 mg
−82.4%
mean
Placebo
+0.3%
mean
1 mg vs Placebo: P < 0.001 versus placebo · 4 mg vs Placebo: P < 0.001 versus placebo · 8 mg vs Placebo: P < 0.001 versus placebo · 12 mg vs Placebo: P < 0.001 versus placebo
Further findings
| Outcome | Values |
|---|---|
| Normal liver fat (<5%) achieved · 24 weeks | 1 mg 27% · 4 mg 52% · 8 mg 79% · 12 mg 86% · Placebo 0% |
Correlates of liver fat reduction
- Liver fat (LF) reductions significantly related to changes in body weight, abdominal fat and metabolic measures associated with improved insulin sensitivity and lipid metabolism
Original publication
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. Published 10 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →